Supernus Pharmaceuticals reported $100.48M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbott ABT:US $ 2.74B 44M
Aerie Pharmaceuticals AERI:US $ 28.15M 3.38M
Ani Pharmaceuticals ANIP:US $ 31.96M 3.14M
Aurora Cannabis Inc ACB:CN 43.17M 3.69M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Canopy Growth Corp WEED:CN C$ 108.85M 1.48M
Cara Therapeutics CARA:US $ 7.54M 1.78M
Corcept Therapeutics CORT:US $ 37.81M 264K
Eisai 4523:JP 92.31B 18.18B
Eli Lilly And LLY:US $ 1.63B 67.2M
Endo International Ordinary Shares ENDP:US 180.83M 45.18M
Horizon Pharma HZNP:US 398.22M 25.49M
JAZZ PHA JAZZ:US 325.67M 16.86M
Lannett LCI:US $ 17.57M 1.22M
Marinus Pharmaceuticals MRNS:US 17.06M 5.32M
Pacira Pharmaceuticals PCRX:US $ 65M 743K
Perrigo Ordinary Shares PRGO:US 338.1M 55.8M
Pfizer PFE:US $ 3.2B 506M
Revance Therapeutics RVNC:US $ 46.19M 2.21M
Supernus Pharmaceuticals SUPN:US $ 100.48M 10.02M
Teva Pharmaceutical Industries TEVA:US 849M 30M
United Therapeutics UTHR:US $ 141.5M 62.5M
Xeris Pharmaceuticals Inc XERS:US $ 32.98M 5.67M